Saturday, July 11, 2026

pharma · Chikungunya Virus

Bavarian Nordic

Bavarian Nordic A/S is a pharma organization headquartered in HELLERUP, DK. Primary therapeutic focus areas include Chikungunya Virus. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s)

Copenhagen, DK HQ
1994 Founded
1,730 Employees
EMA registrant Type
Company details
Status
Public
HQ
Copenhagen, DK
Founded
1994
Employees
1,730
Programs
1
Drugs
1
Patents
25

Quick answer

Bavarian Nordic A/S is a pharma organization headquartered in HELLERUP, DK. Primary therapeutic focus areas include Chikungunya Virus. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 3 (1).

Company snapshot

Bavarian Nordic A/S is a Danish [biotechnology](en.wikipedia.org/wiki/Biotechnology) company focused on the development, manufacturing and commercialization of vaccines. The company is headquartered in [Hellerup](en.wikipedia.org/wiki/Hellerup), [Denmark](en.wikipedia.org/wiki/Denmark), with manufacturing facilities in [Kvistgård](en.wikipedia.org/wiki/Kvistg%C3%A5rd), Denmark and [Thörishaus](en.

  • 1 active pipeline program(s) linked via ClinicalTrials.gov.
  • 25 US patent(s) indexed to this assignee profile.
  • 1 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Bavarian Nordic. Not investment advice.

Lead pipeline drugs

Active clinical programs

Momentum signals

Momentum

Proprietary activity score for Bavarian Nordic.

1 active signal

13 /100 +0 vs 30 days ago

Signal breakdown

  • Clinical trials 2 30d
  • Nova articles 0 30d
  • Patents filed 0 30d
  • FDA actions 0 30d
  • SEC filings 0 30d
  • Conference presentations 0 90d
  • Pipeline advances 0 30d
Competitive landscape
Recent activity

Quick answers

Common questions about this sponsor — for analysts and search.

  • What is Bavarian Nordic?

    Bavarian Nordic A/S is a pharma organization headquartered in HELLERUP, DK. Primary therapeutic focus areas include Chikungunya Virus. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, an

  • Is Bavarian Nordic publicly traded?

    Bavarian Nordic appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

  • What drugs does Bavarian Nordic develop or market?

    We link 1 drug profile(s) where Bavarian Nordic is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/bavarian-nordic-a-s#company-drugs.

  • What are the latest developments for Bavarian Nordic?

    In the last 12 months our linked public records show 1 trial program update(s) and 0 US patent grant(s) tied to this profile.

  • What therapeutic areas does Bavarian Nordic focus on?

    Bavarian Nordic focuses on Chikungunya Virus based on our analysis of their pipeline programs and drug development activities.

Therapeutic focus

Therapeutic area distribution

Pipeline concentration by therapeutic area from linked clinical programs.

Programs by therapeutic area

Others
2